Activaero – novel solutions for severe respiratory diseases

We significantly improve the treatment of severe respiratory diseases and notably increase the quality of life for patients by developing cutting-edge solutions in the field of aerosolized therapies. The unique combination of efficacious, though underutilized, drugs with our unparalleled FAVORITE approach is fuelling a promising pipeline of highly effective, safer and significantly more cost-efficient pulmonary therapies. Activaero has a proven track-record in clinical development and partnering with leading pharma and biotech companies. Our lead product FLAVORESTIN has shown outstanding clinical benefit in a pivotal clinical trial and will soon be filed for market approval in Europe.

• 23.04.2013 - 01.01.1970 Activaero and the University of Giessen Extend Strategic Research and Development Collaboration

  Gemuenden/Wohra, Germany, April 23, 2013 - Activaero GmbH, the therapeutic area specialist for respiratory diseases, today announced the signing of...[more]

  [more]
• 08.04.2013 - 01.01.1970 New Asthma Treatment for Children: Activaero Reports Therapeutic Benefit and High Acceptance from Phase II Trial

  Gemünden/Wohra, Germany, April 8, 2013 – Activaero GmbH, the therapeutic area specialist for respiratory diseases, today announced positive results...[more]

  [more]
• 12.02.2013 - 01.01.1970 Activaero Initiates Proof of Concept Trial with LASAG in Severe Influenza

  Gemünden/Wohra, Germany, February 12, 2013: Activaero GmbH, the therapeutic area specialist for respiratory diseases, today announced that the first...[more]

  [more]